.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Chinese Patent Office
Cerilliant
Mallinckrodt
McKinsey
Johnson and Johnson
McKesson
UBS
Covington

Generated: December 13, 2017

DrugPatentWatch Database Preview

RAPIVAB Drug Profile

« Back to Dashboard

Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-seven patent family members in twenty-seven countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

Summary for RAPIVAB

Drug patent expirations by year for RAPIVAB

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
BiocrystRAPIVABperamivirSOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
BiocrystRAPIVABperamivirSOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
BiocrystRAPIVABperamivirSOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
BiocrystRAPIVABperamivirSOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
BiocrystRAPIVABperamivirSOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: RAPIVAB

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,770,427Antiviral treatments► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RAPIVAB

Country Document Number Estimated Expiration
Japan2013256527► Subscribe
Eurasian Patent Organization200870263► Subscribe
China104784166► Subscribe
Mexico2008013140► Subscribe
Canada2315262► Subscribe
Poland196674► Subscribe
Slovenia1040094► Subscribe
Canada2642260► Subscribe
Australia2200199► Subscribe
Australia2007215156► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Moodys
Fish and Richardson
Cantor Fitzgerald
Deloitte
Farmers Insurance
Baxter
US Department of Justice
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot